Business Wire

IDEMIA

26.6.2020 10:32:12 CEST | Business Wire | Press release

Share
IDEMIA and Treezor Launch the First Eco-friendly Payment Card by Onlyone, a French Fintech Firm

IDEMIA teamed up with Treezor over three years ago to develop a broad range of groundbreaking products like metal cards and new look / new-feel cards – colored layers, bushed metal finish, transparent - targeting key French neobanks and fintechs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005102/en/

This collaboration between IDEMIA, the global leader in Augmented Identity and Treezor the French banking-as-a-service market leader, has today culminated in the launch of the first ever eco-friendly card by a fintech in France. This move ties in with both companies’ green initiatives while meeting consumer demand for sustainable solutions.

Backed by longstanding design, development and production know-how, IDEMIA was able to offer Treezor a low-natural-resource-consuming card without compromising at all on security or end-user convenience. As part of its environmental strategy, IDEMIA reaffirms its commitment to move away from today’s linear take-make-waste model and fundamentally rethink the way we design, use and reuse plastics.

Onlyone, first eco-friendly neobank1

Onlyone2 , a startup that markets itself as the first ever genuinely environmentally friendly fintech, will be the first recipient of this new 85+% recycled PVC card that is due to be launched with its existing customers in September 2020.

“We strive to adopt green practices throughout our operations by going paperless and developing digital and eco-friendly bank card solutions. Bank cards are manufactured from industrial waste-based recycled PVC in line with circular economy principles, which seek to cut waste of natural resources and minimize industrial waste. IDEMIA also obtained “Environmental Claim Validation Summary” certification from its recycled PVC supplier “UL Environment Inc.” said Amanda Gourbault, Executive Vice-President for Financial institutions activities at IDEMIA.

"We are grateful Treezor and IDEMIA give us this amazing opportunity to be the first Fintech in France to offer an eco-responsible card. With this new card, we are laying the first brick in supporting our customers towards a low-carbon lifestyle" said Kamel Nait Outaleb, Co-founder and CEO of Onlyone .

“We are proud that Onlyone will issue this very first card that embraces our and Onlyone’s values and meets today’s consumer expectations. We are thrilled to have a chance to contribute to #Tech4Good who share what we are trying to achieve. A big thank you to IDEMIA for bringing its technological expertise” said Eric Lassus, Treezor cofounder and CEO.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

About Onlyone:

Created at the end of 2018, Onlyone is an independent, 100% digital, ethical and positive impact Fintech. Founded by Kamel Naït-Outaleb, Amine Melouk and Matthias Rouberol, three experienced entrepreneurs in banking and digital, its mission is to create a different, more virtuous payment account model, in order to reposition the banking world at the heart of society and the realities of our time.

To meet social and environmental challenges, Onlyone is reinventing account management services, adapting them to help create a transparent and sustainable banking world. In addition to monitoring day-to-day account operations, Fintech enables its users to understand, monitor and reduce the environmental impact of their consumption thanks to an exclusive environmental impact score and change management tools. It also enables them to contribute to financing projects with a high social and environmental impact, such as carbon offsetting projects or the fight against malnutrition, in a simple way and at no extra cost. To find out more go to Onlyonecard.eu.

About Treezor

Éric Lassus and Xavier Labouret founded Treezor in 2016 and in 2019 sold it to French bank Société Générale. Today Treezor is a French white-label payment services fintech. The firm can market its services in Europe based on its electronic money operating license and its Mastercard principal member status. The firm manages the entire payment process via its platform encompassing purchase, card issue, Xpay, wire transfers, P2P, KYC and more. The firm dedicates a large proportion of its funds to developing new technologies and has 80-plus staff in Paris and Rennes. To learn more about Treezor, go to www.treezor.com , follow us on Twitter @TreezorBanking and on our LinkedIn page.

----------------------------

1 As defined by the French Prudential Supervision and Resolution Authority in its 2019 report titled “Neobanks seeking profits”, ‘neobank’ means Banking-as-a-Service platforms like Treezor.
2 Treezor payment services agent

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye